Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

NCT02262533

Last updated date
Study Location
Bms Clinical Research Center
Hamilton, New Jersey, 08690, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
N/A - Healthy Subjects
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-45 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECGs), and clinical laboratory determinations

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any significant acute or chronic medical illness, history of hypotension, history or
evidence of abnormal bleeding or coagulation disorders, significant head injury within
the last 2 years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

N/A - Healthy SubjectsPhase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects
NCT02262520
ALL GENDERS
18 Years+
years
MULTIPLE SITES
N/A - Healthy SubjectsPhase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
NCT02262533
  1. Hamilton, New Jersey
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
Official Title  ICMJE Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
Brief Summary The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE N/A - Healthy Subjects
Intervention  ICMJE
  • Drug: Apixaban
  • Drug: Atenolol
Study Arms  ICMJE
  • Experimental: Treatment A: Apixaban
    Apixaban tablet by mouth on specified day
    Intervention: Drug: Apixaban
  • Experimental: Treatment B: Atenolol
    Atenolol tablet by mouth on specified day
    Intervention: Drug: Atenolol
  • Experimental: Treatment C: Apixaban and Atenolol
    Apixaban and Atenolol tablets by mouth on specified day
    Interventions:
    • Drug: Apixaban
    • Drug: Atenolol
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 9, 2014)
15
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE June 2007
Actual Primary Completion Date June 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECGs), and clinical laboratory determinations

Exclusion Criteria:

  • Any significant acute or chronic medical illness, history of hypotension, history or evidence of abnormal bleeding or coagulation disorders, significant head injury within the last 2 years
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02262533
Other Study ID Numbers  ICMJE CV185-033
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Bristol-Myers Squibb
Study Sponsor  ICMJE Bristol-Myers Squibb
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Director:Bristol-Myers SquibbBristol-Myers Squibb
PRS Account Bristol-Myers Squibb
Verification Date August 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP